Loss of stromal caveolin-1 expression in colorectal cancer predicts poor survival

World Journal of Gastroenterology

Volumn 21, Issue 4, 2015, Pages 1140-1147

  Zhao, Zhi ^a   Han, Fang Hai ^a   Yang, Shi Bin ^a   Hua, Li Xin ^a   Wu, Jian Hai ^a   Zhan, Wen Hua ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

CAV 1; Colorectal cancer; Prognosis; Stroma

Indexed keywords

CAVEOLIN 1; CAV1 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL FEATURE; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DISEASE SEVERITY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OVERALL SURVIVAL; PROTEIN EXPRESSION; STROMA CELL; ADENOCARCINOMA; CANCER STAGING; CHEMISTRY; CHI SQUARE DISTRIBUTION; COLORECTAL NEOPLASMS; DOWN REGULATION; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; METABOLISM; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK FACTOR; TIME FACTOR; TUMOR RECURRENCE; VERY ELDERLY; YOUNG ADULT;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CAVEOLIN 1; CHI-SQUARE DISTRIBUTION; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; DOWN-REGULATION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; STROMAL CELLS; TIME FACTORS; YOUNG ADULT;

EID: 84921717718     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i4.1140     Document Type: Article

References (32)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30 [PMID: 23335087 doi: 10.3322/caac.21166]
2. Sinclair P, Singh A, Riaz AA, Amin A. An unsolved conundrum: the ideal follow-up strategy after curative surgery for colorectal cancer. Gastrointest Endosc 2012; 75: 1072-1079 [PMID: 22520880 doi: 10.1016/j.gie.2012.01.004]
3. Togo S, Polanska UM, Horimoto Y, Orimo A. Carcinoma-associated fibroblasts are a promising therapeutic target. Cancers (Basel) 2013; 5: 149-169 [PMID: 24216702 doi: 10.3390/cancers5010149]
4. Polanska UM, Orimo A. Carcinoma-associated fibroblasts: nonneoplastic tumour-promoting mesenchymal cells. J Cell Physiol 2013; 228: 1651-1657 [PMID: 23460038 doi: 10.1002/jcp.24347]
5. Shimoda M, Mellody KT, Orimo A. Carcinoma-associated fibroblasts are a rate-limiting determinant for tumour progression. Semin Cell Dev Biol 2010; 21: 19-25 [PMID: 19857592 doi: 10.1016/j.semcdb.2009.10.002]
6. Martinez-Outschoorn UE, Lisanti MP, Sotgia F. Catabolic cancerassociated fibroblasts transfer energy and biomass to anabolic cancer cells, fueling tumor growth. Semin Cancer Biol 2014; 25: 47-60 [PMID: 24486645 doi: 10.1016/j.semcancer.2014.01.005]
7. Pavlides S, Vera I, Gandara R, Sneddon S, Pestell RG, Mercier I, Martinez-Outschoorn UE, Whitaker-Menezes D, Howell A, Sotgia F, Lisanti MP. Warburg meets autophagy: cancer-associated fibroblasts accelerate tumor growth and metastasis via oxidative stress, mitophagy, and aerobic glycolysis. Antioxid Redox Signal 2012; 16: 1264-1284 [PMID: 21883043 doi: 10.1089/ars.2011.4243]
8. Parton RG, Hanzal-Bayer M, Hancock JF. Biogenesis of caveolae: a structural model for caveolin-induced domain formation. J Cell Sci 2006; 119: 787-796 [PMID: 16495479 doi: 10.1242/jcs.02853]
9. Parton RG. Cell biology. Life without caveolae. Science 2001; 293: 2404-2405 [PMID: 11577223 doi: 10.1126/science.1065677]
10. Mercier I, Jasmin JF, Pavlides S, Minetti C, Flomenberg N, Pestell RG, Frank PG, Sotgia F, Lisanti MP. Clinical and translational implications of the caveolin gene family: lessons from mouse models and human genetic disorders. Lab Invest 2009; 89: 614-623 [PMID: 19333235 doi: 10.1038/labinvest.2009.23]
11. Couet J, Li S, Okamoto T, Ikezu T, Lisanti MP. Identification of peptide and protein ligands for the caveolin-scaffolding domain. Implications for the interaction of caveolin with caveolaeassociated proteins. J Biol Chem 1997; 272: 6525-6533 [PMID: 9045678 doi: 10.1074/jbc.272.10.6525]
12. Williams TM, Medina F, Badano I, Hazan RB, Hutchinson J, Muller WJ, Chopra NG, Scherer PE, Pestell RG, Lisanti MP. Caveolin-1 gene disruption promotes mammary tumorigenesis and dramatically enhances lung metastasis in vivo. Role of Cav-1 in cell invasiveness and matrix metalloproteinase (MMP-2/9) secretion. J Biol Chem 2004; 279: 51630-51646 [PMID: 15355971 doi: 10.1074/jbc.M409214200]
13. Qian N, Ueno T, Kawaguchi-Sakita N, Kawashima M, Yoshida N, Mikami Y, Wakasa T, Shintaku M, Tsuyuki S, Inamoto T, Toi M. Prognostic significance of tumor/stromal caveolin-1 expression in breast cancer patients. Cancer Sci 2011; 102: 1590-1596 [PMID: 21585620 doi: 10.1111/j.1349-7006.2011.01985.x]
14. Steffens S, Schrader AJ, Blasig H, Vetter G, Eggers H, Tränkenschuh W, Kuczyk MA, Serth J. Caveolin 1 protein expression in renal cell carcinoma predicts survival. BMC Urol 2011; 11: 25 [PMID: 22152020 doi: 10.1186/1471-2490-11-25]
15. El-Gendi SM, Mostafa MF, El-Gendi AM. Stromal caveolin-1 expression in breast carcinoma. Correlation with early tumor recurrence and clinical outcome. Pathol Oncol Res 2012; 18: 459-469 [PMID: 22057638 doi: 10.1007/s12253-011-9469-5]
16. Witkiewicz AK, Dasgupta A, Sotgia F, Mercier I, Pestell RG, Sabel M, Kleer CG, Brody JR, Lisanti MP. An absence of stromal caveolin-1 expression predicts early tumor recurrence and poor clinical outcome in human breast cancers. Am J Pathol 2009; 174: 2023-2034 [PMID: 19411448 doi: 10.2353/ajpath.2009.080873]
17. Ayala G, Morello M, Frolov A, You S, Li R, Rosati F, Bartolucci G, Danza G, Adam RM, Thompson TC, Lisanti MP, Freeman MR, Di Vizio D. Loss of caveolin-1 in prostate cancer stroma correlates with reduced relapse-free survival and is functionally relevant to tumour progression. J Pathol 2013; 231: 77-87 [PMID: 23729330 doi: 10.1002/path.4217]
18. Jia Y, Wang N, Wang J, Tian H, Ma W, Wang K, Tan B, Zhang G, Yang S, Bai B, Cheng Y. Down-regulation of stromal caveolin-1 expression in esophageal squamous cell carcinoma: a potent predictor of lymph node metastases, early tumor recurrence, and poor prognosis. Ann Surg Oncol 2014; 21: 329-336 [PMID: 23982252 doi: 10.1245/s10434-013-3225-x]
19. Zhao X, He Y, Gao J, Fan L, Li Z, Yang G, Chen H. Caveolin-1 expression level in cancer associated fibroblasts predicts outcome in gastric cancer. PLoS One 2013; 8: e59102 [PMID: 23527097 doi: 10.1371/journal.pone.0059102]
20. Witkiewicz AK, Dasgupta A, Sammons S, Er O, Potoczek MB, Guiles F, Sotgia F, Brody JR, Mitchell EP, Lisanti MP. Loss of stromal caveolin-1 expression predicts poor clinical outcome in triple negative and basal-like breast cancers. Cancer Biol Ther 2010; 10: 135-143 [PMID: 20431349 doi: 10.4161/cbt.10.2.11983]
21. Di Vizio D, Morello M, Sotgia F, Pestell RG, Freeman MR, Lisanti MP. An absence of stromal caveolin-1 is associated with advanced prostate cancer, metastatic disease and epithelial Akt activation. Cell Cycle 2009; 8: 2420-2424 [PMID: 19556867 doi: 10.4161/cc.8.15.9116]
22. Friedrich T, Richter B, Gaiser T, Weiss C, Janssen KP, Einwächter H, Schmid RM, Ebert MP, Burgermeister E. Deficiency of caveolin-1 in Apc(min/+) mice promotes colorectal tumorigenesis. Carcinogenesis 2013; 34: 2109-2118 [PMID: 23640045 doi: 10.1093/carcin/bgt142]
23. Luo T, Wu S, Shen X, Li L. Network cluster analysis of proteinprotein interaction network identified biomarker for early onset colorectal cancer. Mol Biol Rep 2013; 40: 6561-6568 [PMID: 24197691 doi: 10.1007/s11033-013-2694-0]
24. Koleske AJ, Baltimore D, Lisanti MP. Reduction of caveolin and caveolae in oncogenically transformed cells. Proc Natl Acad Sci USA 1995; 92: 1381-1385 [PMID: 7877987 doi: 10.1073/pnas.92.5.1381]
25. Timme TL, Goltsov A, Tahir S, Li L, Wang J, Ren C, Johnston RN, Thompson TC. Caveolin-1 is regulated by c-myc and suppresses c-myc-induced apoptosis. Oncogene 2000; 19: 3256-3265 [PMID: 10918582 doi: 10.1038/sj.onc.1203654]
26. Park DS, Razani B, Lasorella A, Schreiber-Agus N, Pestell RG, Iavarone A, Lisanti MP. Evidence that Myc isoforms transcriptionally repress caveolin-1 gene expression via an INRdependent mechanism. Biochemistry 2001; 40: 3354-3362 [PMID: 11258956 doi: 10.1021/bi002787b]
27. Sotgia F, Martinez-Outschoorn UE, Howell A, Pestell RG, Pavlides S, Lisanti MP. Caveolin-1 and cancer metabolism in the tumor microenvironment: markers, models, and mechanisms. Annu Rev Pathol 2012; 7: 423-467 [PMID: 22077552 doi: 10.1146/annurev-pathol-011811-120856]
28. Razani B, Altschuler Y, Zhu L, Pestell RG, Mostov KE, Lisanti MP. Caveolin-1 expression is down-regulated in cells transformed by the human papilloma virus in a p53-dependent manner. Replacement of caveolin-1 expression suppresses HPV-mediated cell transformation. Biochemistry 2000; 39: 13916-13924 [PMID: 11076533 doi: 10.1021/bi001489b]
29. Bonuccelli G, Whitaker-Menezes D, Castello-Cros R, Pavlides S, Pestell RG, Fatatis A, Witkiewicz AK, Vander Heiden MG, Migneco G, Chiavarina B, Frank PG, Capozza F, Flomenberg N, Martinez-Outschoorn UE, Sotgia F, Lisanti MP. The reverse Warburg effect: glycolysis inhibitors prevent the tumor promoting effects of caveolin-1 deficient cancer associated fibroblasts. Cell Cycle 2010; 9: 1960-1971 [PMID: 20495363 doi: 10.4161/cc.9.10.11601]
30. Sotgia F, Del Galdo F, Casimiro MC, Bonuccelli G, Mercier I, Whitaker-Menezes D, Daumer KM, Zhou J, Wang C, Katiyar S, Xu H, Bosco E, Quong AA, Aronow B, Witkiewicz AK, Minetti C, Frank PG, Jimenez SA, Knudsen ES, Pestell RG, Lisanti MP. Caveolin-1-/-null mammary stromal fibroblasts share characteristics with human breast cancer-associated fibroblasts. Am J Pathol 2009; 174: 746-761 [PMID: 19234134 doi: 10.2353/ajpath.2009.080658]
31. Martinez-Outschoorn UE, Pavlides S, Whitaker-Menezes D, Daumer KM, Milliman JN, Chiavarina B, Migneco G, Witkiewicz AK, Martinez-Cantarin MP, Flomenberg N, Howell A, Pestell RG, Lisanti MP, Sotgia F. Tumor cells induce the cancer associated fibroblast phenotype via caveolin-1 degradation: implications for breast cancer and DCIS therapy with autophagy inhibitors. Cell Cycle 2010; 9: 2423-2433 [PMID: 20562526 doi: 10.4161/cc.9.12.12048]
32. Pavlides S, Whitaker-Menezes D, Castello-Cros R, Flomenberg N, Witkiewicz AK, Frank PG, Casimiro MC, Wang C, Fortina P, Addya S, Pestell RG, Martinez-Outschoorn UE, Sotgia F, Lisanti MP. The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. Cell Cycle 2009; 8: 3984-4001 [PMID: 19923890 doi: 10.4161/cc.8.23.10238]